Roy Buchanan

Stock Analyst at JMP Securities

(4.69)
# 182
Out of 5,026 analysts
71
Total ratings
56.52%
Success rate
49.38%
Average return

Stocks Rated by Roy Buchanan

Cidara Therapeutics
Oct 3, 2025
Maintains: Market Outperform
Price Target: $153$173
Current: $105.62
Upside: +63.79%
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $28.44
Upside: +33.61%
Dynavax Technologies
Aug 22, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $9.93
Upside: +222.26%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24$25
Current: $11.65
Upside: +114.54%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16$14
Current: $3.35
Upside: +318.54%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $5.40
Upside: +85.19%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5$2
Current: $1.24
Upside: +61.94%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $2.54
Upside: +608.66%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $57.15
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7$4
Current: $2.52
Upside: +58.73%
Maintains: Market Outperform
Price Target: $23$14
Current: $1.61
Upside: +769.57%
Reiterates: Market Outperform
Price Target: $33
Current: $95.61
Upside: -65.48%
Maintains: Market Outperform
Price Target: $4$5
Current: $4.47
Upside: +11.86%
Maintains: Market Outperform
Price Target: $443$448
Current: $815.61
Upside: -45.07%
Maintains: Market Perform
Price Target: $14$16
Current: $10.61
Upside: +50.80%
Downgrades: Market Perform
Price Target: n/a
Current: $0.85
Upside: -